

Keck School of Medicine of USC

◆ Department of Surgery

Presents

Sarcoma Tumor Board 2024-2025 - 8/16/2024

Activity Information:

Dates & Times: Friday, August 16, 2024 at 7:30 AM – Friday, August 16, 2024 at 8:30 AM

Location: Virtual Conference

AMA Category 1 Credits: 1.00

Speaker(s):

Joseph Femino, MD, FAAOS

University of Southern California

Mark Agulnik, MD

Keck Medicine of USC

Objectives:

- 1 Apply best possible practice to achieve optimal outcomes for sarcoma patients
- 2 Evaluate diagnostic approaches and overall management principles of multimodality treatment of sarcomas
- 3 Appraise new research findings and apply to clinical management of sarcomas

Educational Format: Live Activity

Accreditation Statement(s):

The Keck School of Medicine of the University of Southern California is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Disclosure:

As an organization accredited by the ACCME The Keck School of Medicine of the University of Southern California requires everyone who is in a position to control the content of an education activity to disclose prior to the activity all relevant financial relationships with any commercial interest. All disclosed relevant financial relationships will have been resolved prior to the commencement of the activity.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Joseph Femino, MD, FAAOS	Activity Administrator, Faculty	Stocks or stock options, excluding diversified mutual funds-Stryker Stocks or stock options, excluding diversified mutual funds-Intuitive Surgical - 07/03/2024
Mark Agulnik, MD	Activity Administrator, Faculty	Consulting Fee-Deciphera Honoraria-Bayer (Relationship has ended) Consulting Fee-Daiichi Sankyo, Inc. Consulting Fee-Boehringer Ingelheim - 07/03/2024
Priscilla H Choe, RN	Activity Administrator	Nothing to disclose - 07/02/2024

During the course of this activity there may be report and/or discussion of unlabeled or unapproved uses of pharmaceuticals and/or medical devices. All such report and/or discussion are attested to be based on evidence that is generally accepted within the profession of medicine and conforms to the generally accepted standards of experimental design, data collection and analysis.

Support:

None

In accordance with the Americans with Disabilities Act (ADA), please call the CME office at (323)442-2555 should you require special assistance or need additional information regarding this activity.